VR 694

Drug Profile

VR 694

Alternative Names: VR694

Latest Information Update: 08 Nov 2010

Price : $50

At a glance

  • Originator Vectura
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Bronchitis

Most Recent Events

  • 31 May 2007 This programme is still in active development
  • 27 Oct 2005 No development reported - Preclinical for Bronchitis in United Kingdom (Inhalation)
  • 27 Oct 2005 No development reported - Preclinical for Asthma in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top